News
-
-
PRESS RELEASE
Medicus Pharma Ltd. Announces Collaboration with the Gorlin Syndrome Alliance to Pursue Compassionate Use Pathway for Skinject(TM) in Patients with Gorlin Syndrome
Medicus Pharma collaborates with the Gorlin Syndrome Alliance to provide compassionate access to SKINJECT™, a novel therapy for Gorlin Syndrome patients. The initiative aims to collect real-world data and integrate patient insights for future development -
-
PRESS RELEASE
Medicus Pharma Ltd. Announces First Patient Treated in United Arab Emirates (UAE) Sknjct-004 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin
Medicus Pharma enrolls first patient in SKNJCT-004 phase 2 clinical study for non-invasive BCC treatment in UAE with Cleveland Clinic Abu Dhabi as lead investigator -
-
-
-
-
-
PRESS RELEASE
Medicus Pharma Ltd. Receives Positive Feedback From the Food and Drug Adminstration (FDA) Type C Meeting Supporting the Development of Skinject
FDA agrees to 505(b)(2) pathway for Medicus Pharma's Skinject D-MNA to treat BCC, positive Type C meeting feedback, SKNJCT-003 patient recruitment aims, EOP2 request in Q1 2026
